- Home
- UYSC vs ACET Comparison
UYSC vs ACET Comparison
Compare UYSC & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UYSC
- ACET
- Stock Information
- Founded
- UYSC 2024
- ACET 1947
- Country
- UYSC United States
- ACET United States
- Employees
- UYSC N/A
- ACET N/A
- Industry
- UYSC Blank Checks
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- UYSC Finance
- ACET Health Care
- Exchange
- UYSC Nasdaq
- ACET Nasdaq
- Market Cap
- UYSC 76.5M
- ACET 63.8M
- IPO Year
- UYSC 2025
- ACET N/A
- Fundamental
- Price
- UYSC $10.08
- ACET $0.71
- Analyst Decision
- UYSC
- ACET Strong Buy
- Analyst Count
- UYSC 0
- ACET 7
- Target Price
- UYSC N/A
- ACET $5.60
- AVG Volume (30 Days)
- UYSC 2.7K
- ACET 386.5K
- Earning Date
- UYSC 01-01-0001
- ACET 08-12-2025
- Dividend Yield
- UYSC N/A
- ACET N/A
- EPS Growth
- UYSC N/A
- ACET N/A
- EPS
- UYSC N/A
- ACET N/A
- Revenue
- UYSC N/A
- ACET N/A
- Revenue This Year
- UYSC N/A
- ACET N/A
- Revenue Next Year
- UYSC N/A
- ACET N/A
- P/E Ratio
- UYSC N/A
- ACET N/A
- Revenue Growth
- UYSC N/A
- ACET N/A
- 52 Week Low
- UYSC $10.05
- ACET $0.45
- 52 Week High
- UYSC $11.00
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- UYSC N/A
- ACET 53.15
- Support Level
- UYSC N/A
- ACET $0.75
- Resistance Level
- UYSC N/A
- ACET $0.82
- Average True Range (ATR)
- UYSC 0.00
- ACET 0.04
- MACD
- UYSC 0.00
- ACET 0.00
- Stochastic Oscillator
- UYSC 0.00
- ACET 44.88
About UYSC UY Scuti Acquisition Corp. Ordinary Shares
UY Scuti Acquisition Corp is a newly organized blank check company.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.